Home >> Signaling Pathways >> JAK/STAT Signaling >> EGFR

EGFR

EGFR (epidermal growth factor receptor) is the cell-surface receptor of its specific ligands, including epidermal growth factor and TGFα (transforming growth factor α) and is a receptor tyrosine kinase.

Products for  EGFR

  1. Cat.No. Product Name Information
  2. GC11015 PD168393 EGFR inhibitor PD168393  Chemical Structure
  3. GC17473 Pelitinib (EKB-569) Pelitinib (EKB-569) (EKB-569;WAY-EKB 569) is an irreversible inhibitor of EGFR with an IC50 of 38.5 nM; also slightly inhibits Src, MEK/ERK and ErbB2 with IC50s of 282, 800, and 1255 nM, respectively. Pelitinib (EKB-569)  Chemical Structure
  4. GC34210 Pertuzumab (Anti-Human HER2, Humanized Antibody)

    Pertuzumab (Anti-Human HER2, Humanized Antibody), the first of a new class of agents designated as HER dimerisation inhibitors, is a humanised IgG1 monoclonal antibody (mAb) that sterically binds domain II of the erbB2 receptor .

    Pertuzumab (Anti-Human HER2, Humanized Antibody)  Chemical Structure
  5. GC69690 Petosemtamab

    Petosemtamab (MCLA 158) is a monoclonal antibody (mAb) that targets both EGFR (Kd: 0.22 nM) and LGR5 (Kd: 0.86 nM). Petosemtamab blocks EGFR signaling and receptor degradation in LGR5+ cancer cells. It can be used for research on solid tumors such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC), etc.

    Petosemtamab  Chemical Structure
  6. GC32927 PF-06459988 PF-06459988 is an orally activity, irreversible and mutant-selective inhibitor of EGFR mutant forms. PF-06459988 demonstrates high potency and specificity to the T790M-containing double mutant EGFRs. PF-06459988 can be used for the research of cancer. PF-06459988  Chemical Structure
  7. GC40915 PKI-166 An inhibitor of EGFR PKI-166  Chemical Structure
  8. GC69728 Ponezumab

    Ponezumab (PF-04360365) is a humanized monoclonal antibody against amyloid beta protein of the IgG2 class. Ponezumab can reduce Aβ levels in the central nervous system and improve performance in various learning and memory models in mice. Ponezumab can be used for research on Alzheimer's disease.

    Ponezumab  Chemical Structure
  9. GC17916 Poziotinib A irreversible pan-HER inhibitor Poziotinib  Chemical Structure
  10. GC32733 Pyrotinib (SHR-1258) Pyrotinib (SHR-1258) (SHR-1258) is a potent and selective EGFR/HER2 dual inhibitor with IC50s of 13 and 38 nM, respectively. Pyrotinib (SHR-1258)  Chemical Structure
  11. GC32989 Pyrotinib dimaleate (SHR-1258 dimaleate) Pyrotinib dimaleate (SHR-1258 dimaleate) (SHR-1258 dimaleate) is a potent and selective EGFR/HER2 dual inhibitor with IC50s of 13 and 38 nM, respectively. Pyrotinib dimaleate (SHR-1258 dimaleate)  Chemical Structure
  12. GC12038 RG 13022 EGFR tyrosine kinase inhibitor RG 13022  Chemical Structure
  13. GC10217 RG-14620 inhibitor of epidermal growth factor (EGF) receptor kinase RG-14620  Chemical Structure
  14. GC33061 Rociletinib hydrobromide (CO-1686 (hydrobromide)) Rociletinib hydrobromide (CO-1686 (hydrobromide)) (CO-1686 hydrobromide) is an orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR including T790M, and the Ki values for EGFRL858R/T790M and EGFRWT are 21.5 nM and 303.3 nM, respectively. Rociletinib hydrobromide (CO-1686 (hydrobromide))  Chemical Structure
  15. GC37568 RTC-5 RTC-5 (TRC-382) is an optimized phenothiazine with anti-cancer potency. RTC-5 demonstrates efficacy against a xenograft model of an EGFR driven cancer, its effects is attributed to concomitant negative regulation of PI3K-AKT and RAS-ERK signaling. RTC-5  Chemical Structure
  16. GC69843 Ruserontinib

    Ruserontinib (SKLB1028) is an orally active inhibitor of EGFR, FLT3, and Abl kinases with an IC50 value of 55 nM against human FLT3. It has anti-tumor activity.

    Ruserontinib  Chemical Structure
  17. GC68430 Selatinib Selatinib  Chemical Structure
  18. GC11172 TAK-285 HER2/EGFR(HER1) inhibitor TAK-285  Chemical Structure
  19. GC32100 Tarloxotinib bromide (TH-4000) Tarloxotinib bromide (TH-4000) (TH-4000) is an irreversible EGFR/HER2 inhibitor. Tarloxotinib bromide (TH-4000)  Chemical Structure
  20. GC65310 TAS0728 TAS0728 is a potent, selective, orally active, irreversible and covalent-binding HER2 inhibitor, with an IC50 of 13 nM. TAS0728 also shows IC50s of 4.9, 8.5, 31, 65, 33, 25 and 86 nM for BMX、HER4、BLK、EGFR、JAK3、SLK and LOK respectively. Furthermore, TAS0728 exhibits robust and sustained inhibition of the phosphorylation of HER2 TAS0728  Chemical Structure
  21. GC32752 TAS6417 TAS6417 (CLN-081) is a highly effective, orally active and pan-mutation-selective EGFR tyrosine kinase inhibitor with a unique scaffold fitting into the ATP-binding site of the EGFR hinge region, with IC50 values ranging from 1.1-8.0 nM. TAS6417  Chemical Structure
  22. GC41577 Tephrosin (synthetic) Tephrosin (synthetic) is a natural rotenoid which has potent antitumor activities. Tephrosin (synthetic) induces degradation of of EGFR and ErbB2 by inducing internalization of the receptors. Tephrosin (synthetic)  Chemical Structure
  23. GC31752 Tesevatinib (XL-647) Tesevatinib (XL-647) (XL-647; EXEL-7647; KD-019) is an orally available, multi-target tyrosine kinase inhibitor; inhibits EGFR, ErbB2, KDR, Flt4 and EphB4 kinase with IC50s of 0.3, 16, 1.5, 8.7, and 1.4 nM. Tesevatinib (XL-647)  Chemical Structure
  24. GC38081 Theliatinib Theliatinib (Xiliertinib) is a potent, ATP-competitive, orally active and highly selective EGFR inhibitor with a Ki of 0.05 nM and an IC50 of 3 nM. Theliatinib has an IC50 of 22 nM for EGFR T790M/L858R mutant. Theliatinib shows >50-fold selectivity for EGFR than other kinases. Anti-tumor activity. Theliatinib  Chemical Structure
  25. GC34215 Trastuzumab (Anti-Human HER2, Humanized Antibody) Trastuzumab (Anti-Human HER2, Humanized Antibody) is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab (Anti-Human HER2, Humanized Antibody) has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research. Trastuzumab (Anti-Human HER2, Humanized Antibody)  Chemical Structure
  26. GC32726 Tucatinib (Irbinitinib) Tucatinib (Irbinitinib) (Irbinitinib) is a potent, orally active and selective HER2 inhibitor with an IC50 of 8 nM. Tucatinib (Irbinitinib)  Chemical Structure
  27. GC34847 TX1-85-1 An ErbB3 inhibitor TX1-85-1  Chemical Structure
  28. GC19364 Tyrphostin AG 528 Tyrphostin AG 528 is an inhibitor of EGFR and ErbB2 with IC50s of 4.9 and 2.1 uM, respectively. Tyrphostin AG 528  Chemical Structure
  29. GC15271 Tyrphostin AG 879 HER2 inhibitor Tyrphostin AG 879  Chemical Structure
  30. GC38125 Tyrphostin AG30 Tyrphostin AG30 (AG30) is a potent and selective EGFR tyrosine kinase inhibitor. Tyrphostin AG30 (AG30) selectively inhibits self renewal induction by c-ErbB, and is able to inhibit activation of STAT5 by c-ErbB in primary erythroblasts. Tyrphostin AG30  Chemical Structure
  31. GC12249 Varlitinib (ARRY334543) Varlitinib (ARRY334543) (ASLAN001) is a potent, reversible, small molecule pan-EGFR inhibitor with IC50s of 7, 2, 4 nM for HER1, HER2 and HER4, respectively. Varlitinib (ARRY334543)  Chemical Structure
  32. GC16000 WHI-P180 EGFR/Janus Kinase 3 inhibitor WHI-P180  Chemical Structure
  33. GC37933 WHI-P180 hydrochloride WHI-P180 (Janex 3) is a multi-kinase inhibitor; inhibits RET, KDR and EGFR with IC50s of 5 nM, 66 nM and 4 μM, respectively. WHI-P180 hydrochloride  Chemical Structure
  34. GC13213 WZ3146 Mutant EGFR inhibitor, potent and irreversible WZ3146  Chemical Structure
  35. GC15494 WZ4002 Mutant-selective EGFR inhibitor(L858R,T790M), irreversible and potent WZ4002  Chemical Structure
  36. GC11250 WZ8040 EGFR T790M inhibitor,irreversible amd potent WZ8040  Chemical Structure
  37. GC70164 Zalutumumab

    Zalutumumab is a highly affinity pure human IgG1 monoclonal antibody that targets EGFR. Zalutumumab binds to domain III of the epidermal growth factor receptor, exerting its effects by blocking the binding of epidermal growth factor and interfering with the receptor's active conformation. The EC50 values for Zalutumumab with IgG and its Fab regions are 7 and 19 nM, respectively. Zalutumumab can be used in cancer research.

    Zalutumumab  Chemical Structure
  38. GC70165 Zanidatamab

    Zanidatamab (ZW25) is a human bispecific monoclonal antibody targeting 2 different HER2 epitopes (ECD2 and ECD4). Zanidatamab has anti-tumor activity.

    Zanidatamab  Chemical Structure
  39. GC33171 ZD-4190 ZD-4190 is a potent, orally available inhibitor of the vascular endothelial cell growth factor receptor 2 (VEGFR2) and of epidermal growth factor receptor (EGFR) signalling, used for the treatment of cancer. ZD-4190  Chemical Structure
  40. GC70169 Zenocutuzumab

    Zenocutuzumab (MCLA-128) is a bispecific humanized IgG1 antibody that contains two different Fab arms targeting the extracellular domains of HER2 and HER3.

    Zenocutuzumab  Chemical Structure

Items 101 to 139 of 139 total

per page
  1. 1
  2. 2

Set Descending Direction